These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 17868718)
1. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. Peddada AV; Jennings SB; Faricy PO; Walsh RA; White GA; Monroe AT J Urol; 2007 Nov; 178(5):1963-7. PubMed ID: 17868718 [TBL] [Abstract][Full Text] [Related]
2. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. Kollmeier MA; Stock RG; Cesaretti J; Stone NN J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274 [TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity. Monroe AT; Faricy PO; Jennings SB; Biggers RD; Gibbs GL; Peddada AV Brachytherapy; 2008; 7(1):7-11. PubMed ID: 18299109 [TBL] [Abstract][Full Text] [Related]
4. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation. Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801 [TBL] [Abstract][Full Text] [Related]
5. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332 [TBL] [Abstract][Full Text] [Related]
6. Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. Luo HL; Fang FM; Chuang YC; Chiang PH BJU Int; 2009 Dec; 104(11):1620-3. PubMed ID: 19624535 [TBL] [Abstract][Full Text] [Related]
7. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851 [TBL] [Abstract][Full Text] [Related]
8. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149 [TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Stone NN; Stock RG Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161 [TBL] [Abstract][Full Text] [Related]
10. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy. Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108 [TBL] [Abstract][Full Text] [Related]
11. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Lee HK; Adams MT; Motta J Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939 [TBL] [Abstract][Full Text] [Related]
14. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. Phan TP; Syed AM; Puthawala A; Sharma A; Khan F J Urol; 2007 Jan; 177(1):123-7; discussion 127. PubMed ID: 17162020 [TBL] [Abstract][Full Text] [Related]
15. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239 [TBL] [Abstract][Full Text] [Related]
16. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305 [TBL] [Abstract][Full Text] [Related]
17. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. Pellizzon AC; Salvajoli JV; Maia MA; Ferrigno R; Novaes PE; Fogarolli RC; Pellizzon RJ J Urol; 2004 Mar; 171(3):1105-8. PubMed ID: 14767280 [TBL] [Abstract][Full Text] [Related]
18. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study. Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785 [TBL] [Abstract][Full Text] [Related]
19. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Moran BJ; Stutz MA; Gurel MH Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):392-6. PubMed ID: 15145153 [TBL] [Abstract][Full Text] [Related]
20. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]